evipedia.ai ← Back

DGL for Health & Longevity

Evidence Review created on 07/26/2026 using AI4L / Opus 4.8

Also known as: Deglycyrrhizinated Licorice, Deglycyrrhizinated Liquorice, DGL Licorice, Glycyrrhiza glabra (deglycyrrhizinated)

Motivation

DGL, short for deglycyrrhizinated licorice, is a processed form of licorice root in which most of the compound that can raise blood pressure and lower potassium has been stripped away. What remains is a mix of plant flavonoids that coat and soothe the lining of the stomach and gut. Because the troublesome compound is largely gone, DGL can be used far more comfortably over longer periods than ordinary licorice, which is the main reason it draws interest from people focused on digestive comfort and long-term health.

Licorice has been used as a stomach remedy for thousands of years, and the deglycyrrhizinated version was developed in the mid-twentieth century specifically to keep the soothing benefits while removing the side effects. Today it is a common non-prescription option for heartburn, indigestion, mouth ulcers, and irritation of the stomach lining.

This review examines what the evidence shows about DGL: how it appears to work, where the benefits are best supported and where they remain uncertain, the safety issues tied to product quality, and how it is typically used. It focuses on what the research and experienced practitioners report, not on what any individual should do.

Benefits - Risks - Protocol - Conclusion

This section lists high-quality, accessible overviews of DGL from clinicians and trusted health publications that discuss the compound and its digestive uses in depth.

Note: Of the five priority experts, only Chris Kresser and Life Extension had directly relevant DGL content, which is included above. No relevant DGL-specific material was found from Rhonda Patrick, Peter Attia, or Andrew Huberman despite web and on-platform searches.

Grokipedia

  • Liquorice

    Grokipedia’s dedicated Liquorice article covers the plant’s chemistry, its glycyrrhizin content and the deglycyrrhizinated (DGL) form, and its medicinal uses including peptic-ulcer and mucosal applications, providing a broad reference overview of the intervention.

Examine

  • Licorice

    Examine’s research-graded supplement page summarizes the human evidence for licorice and its deglycyrrhizinated form, grading outcomes such as dyspepsia and reflux and flagging the glycyrrhizin-related safety issues.

ConsumerLab

Systematic Reviews

The following systematic reviews and meta-analyses summarize the highest-tier evidence on licorice and its deglycyrrhizinated preparations across the digestive and mucosal conditions for which DGL is used.

Mechanism of Action

DGL works mainly at the surface of the digestive tract rather than through the bloodstream. Ordinary licorice root is dominated by glycyrrhizin (glycyrrhizic acid), which the body converts to glycyrrhetinic acid; both block an enzyme called 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2, an enzyme that normally inactivates the stress hormone cortisol in the kidney). When that enzyme is blocked, cortisol acts like the salt-retaining hormone aldosterone, causing sodium and water retention, potassium loss, and higher blood pressure. Deglycyrrhizination removes most of this compound (to below roughly 3%), leaving the flavonoid fraction while stripping out the mineralocorticoid effect.

The remaining flavonoids — chiefly glabridin, liquiritigenin, isoliquiritigenin, licochalcone A, and glabrene — are thought to be the active gut-protective agents. Proposed mechanisms include:

  • Enhanced mucosal defense: DGL increases the secretion of protective mucus, raises local prostaglandin levels (signaling molecules that maintain the stomach’s protective barrier), improves blood flow to damaged mucosa, and prolongs the lifespan of the cells lining the gut.

  • Anti-inflammatory and antioxidant activity: licorice flavonoids dampen inflammatory signaling and neutralize reactive oxygen species, which may reduce mucosal irritation.

  • Anti-Helicobacter activity: in laboratory work, the flavonoid-rich extract inhibits H. pylori by interfering with the bacterial enzymes DNA gyrase (which coils bacterial DNA) and dihydrofolate reductase (needed to make DNA building blocks), and by inhibiting bacterial protein synthesis; glabridin is the most active constituent, while glycyrrhizin is inactive.

Two views coexist on how much DGL matters systemically. One holds that the benefits are essentially local and topical, so DGL’s value is confined to tissues it directly contacts. The other proposes that absorbed flavonoids exert modest bloodstream-level antioxidant and hormonal effects; the human evidence for meaningful systemic action beyond the gut remains limited.

Because DGL is a botanical extract rather than a single drug, formal pharmacokinetics are not well defined. Glabridin and related flavonoids have low and variable oral absorption, are extensively processed by gut bacteria and the liver, and have relatively short measured half-lives; laboratory studies show glabridin can inhibit certain drug-metabolizing enzymes, though this is not established as clinically important at usual chewed doses.

Historical Context & Evolution

Licorice root has been used for stomach complaints across Egyptian, Greek, Roman, Ayurvedic, and Chinese traditions for millennia. The modern gastrointestinal story began in 1946, when the Dutch physician F.E. Revers observed that a licorice paste healed peptic ulcers in his patients — but also caused facial swelling and high blood pressure in many of them.

That trade-off drove the key innovation. In the 1950s and 1960s, chemists isolated and removed glycyrrhizin, creating deglycyrrhizinated licorice, which retained ulcer-healing activity in early studies without the blood-pressure effect. A related semi-synthetic derivative of glycyrrhetinic acid, carbenoxolone, became a prescription ulcer drug in the 1960s–1970s but retained the mineralocorticoid side effects; DGL was positioned as the safer botanical alternative. Branded DGL-containing products such as Caved-S were studied for gastric and duodenal ulcers through the 1970s and 1980s, generally reporting healing comparable to acid-reducing drugs of that era.

DGL came to be considered for broader health optimization for two reasons. First, the rise of acid-suppressing drugs shifted DGL from a mainstream ulcer therapy to a complementary option favored by people seeking to protect the gut lining without long-term acid suppression. Second, standardized flavonoid extracts (for example, GutGard) revived scientific interest, generating newer controlled trials in indigestion and H. pylori.

The evolution of opinion is ongoing rather than settled. The classic ulcer trials were small and methodologically dated, and acid-suppressing drugs displaced DGL from guidelines — but this reflected the arrival of highly effective competitors as much as any disproof of DGL. Newer standardized-extract trials have renewed, not closed, the question, and both supportive and skeptical readings of the evidence remain defensible.

Expected Benefits

Benefits are framed for health- and longevity-oriented adults considering DGL as a gut-protective option, often as an alternative or complement to long-term acid suppression.

High 🟩 🟩 🟩

Recurrent Canker Sore (Aphthous Ulcer) Relief

Applied topically as a patch, paste, or mouth rinse, licorice extract speeds the healing of recurrent mouth ulcers and reduces their pain and size. This is the best-supported use by modern standards: a systematic review pooled six randomized trials and found consistent, significant benefit through the extract’s anti-inflammatory, antioxidant, and antibacterial actions, with no reported adverse effects. The main limitation is heterogeneity in formulations and dosing across trials, which prevented a formal statistical pooling.

Magnitude: Across six randomized trials (314 subjects), topical licorice significantly reduced ulcer pain and size and shortened healing time to roughly 4–8 days versus controls.

Medium 🟩 🟩

Functional Indigestion (Dyspepsia) Symptom Relief

DGL reduces the discomfort, fullness, and pain of functional dyspepsia — persistent upper-abdominal symptoms without an identifiable structural cause. The proposed basis is improved mucosal protection and reduced low-grade inflammation of the stomach lining. Evidence comes primarily from one well-conducted randomized, double-blind, placebo-controlled trial of a standardized licorice flavonoid extract, supported by mucosal mechanisms; the evidence base is promising but rests on a single modest-sized trial.

Magnitude: In a 30-day randomized trial, 75 mg of a standardized extract twice daily significantly lowered total symptom scores and improved quality-of-life scores versus placebo by day 15 and day 30.

Gastric and Duodenal Ulcer Healing

DGL promotes healing of stomach and upper-intestinal ulcers, historically performing comparably to older acid-reducing drugs while enhancing the gut’s own protective factors rather than suppressing acid. The evidence consists of several small controlled trials from the 1970s–1980s plus more recent extract studies; results are generally positive but the classic trials were small and methodologically dated, and modern head-to-head comparisons against current standard therapy are lacking.

Magnitude: In a controlled trial, 760 mg of DGL three times daily produced roughly 78% reduction in ulcer size versus about 34% with placebo, with complete healing in about 44% versus 6%.

Low 🟩

Acid Reflux (GERD) Symptom Relief

DGL may ease heartburn and regurgitation in gastroesophageal reflux disease (GERD, chronic backflow of stomach contents into the food pipe), thought to work by reinforcing the protective mucus layer of the esophagus and stomach rather than by lowering acid. Support comes from small trials of licorice-containing formulas and consistent clinical reports, but dedicated, well-powered DGL-only reflux trials are scarce, and the effect size relative to standard treatment is not well established.

Magnitude: Small trials of licorice-extract formulas reported clinically meaningful improvement in heartburn and regurgitation beginning around week 2 of treatment; effect size versus standard acid suppression is not quantified.

Helicobacter pylori Suppression

The flavonoid fraction of DGL suppresses H. pylori and may serve as an add-on to standard antibiotic regimens, acting through inhibition of bacterial enzymes and, possibly, reduced bacterial adhesion to the stomach lining. Human evidence is limited to a few small trials plus a broader polyphenol meta-analysis; DGL is best viewed as a potential adjunct, not a stand-alone eradication therapy.

Magnitude: In one randomized study, 150 mg of a standardized extract daily for 60 days produced negative H. pylori tests in about 56% versus about 4% with placebo; as an add-on to triple therapy, polyphenols raised eradication modestly (risk ratio about 1.11).

DGL may protect the stomach lining against irritation from non-steroidal anti-inflammatory drugs (NSAIDs, common painkillers such as ibuprofen and aspirin), by boosting mucus and prostaglandin defenses that these drugs otherwise deplete. The evidence is largely from animal models with limited direct human confirmation, so this benefit is plausible but not clinically proven.

Magnitude: Not quantified in available studies.

Speculative 🟨

Reduced Reliance on Long-Term Acid-Suppressing Drugs

Because DGL soothes and protects the gut lining without suppressing stomach acid, it is proposed as a way to reduce dependence on long-term acid-blocking drugs, whose extended use has been associated in observational data with nutrient malabsorption and other concerns — a longevity-relevant consideration for those seeking to minimize chronic medication. This rationale is mechanistic and indirect; no long-term trial has tested whether DGL use changes hard health outcomes by displacing acid suppression.

Systemic Antioxidant and Anti-Inflammatory Effects

Licorice flavonoids show antioxidant and anti-inflammatory activity in laboratory and animal studies, raising the possibility of modest whole-body benefits relevant to healthy aging. In humans this remains unproven for DGL specifically, and absorption of the active flavonoids is low, so any systemic effect is speculative and based on mechanism and preclinical data only.

Benefit-Modifying Factors

  • Baseline gut status and diagnosis: benefit is greatest when symptoms stem from mucosal irritation, ulceration, or functional dyspepsia; DGL is unlikely to help reflux driven purely by mechanical factors or symptoms unrelated to the gut lining.

  • Helicobacter pylori status: those who are H. pylori-positive may derive additional benefit from DGL’s suppressive activity, whereas H. pylori-negative individuals gain only the mucosal-protective effects.

  • Formulation and chewing: chewable forms mixed with saliva appear more effective for upper-gut and esophageal complaints than swallowed capsules, because contact with the mucosa is central to the mechanism.

  • Concurrent NSAID or alcohol use: people with ongoing mucosal insult from painkillers or alcohol may see clearer protective benefit, since DGL counteracts these specific injuries.

  • Sex-based differences: no consistent sex-based difference in benefit has been established; licorice flavonoids have mild estrogen-like activity, but whether this alters gut benefit by sex is unstudied.

  • Age-related considerations: older adults, who more often have thinned gastric mucosa and take ulcer-promoting medications, may benefit from mucosal support, but they are also more vulnerable to any residual glycyrrhizin, so product quality matters most in this group.

Potential Risks & Side Effects

Risks are framed for health- and longevity-oriented adults using DGL products; the dominant safety issue is not DGL itself but incomplete deglycyrrhizination and product-quality variability.

High 🟥 🟥 🟥

Pseudohyperaldosteronism from Residual Glycyrrhizin

The central risk is that a “DGL” product still contains meaningful glycyrrhizin, which can cause pseudohyperaldosteronism — high blood pressure, low blood potassium (hypokalemia), and fluid retention — by blocking the 11β-HSD2 enzyme. Properly deglycyrrhizinated product carries little of this risk, but independent testing shows many products are under-processed or mislabeled. In severe cases, low potassium can cause muscle weakness, irregular heart rhythms, and, rarely, muscle breakdown; effects are generally reversible once intake stops.

Magnitude: Independent testing found roughly half of tested DGL products contained more glycyrrhizic acid than expected; pseudoaldosteronism from licorice typically appears above about 100 mg of glycyrrhizin per day but has occurred at lower intakes in sensitive people.

Medium 🟥 🟥

Estrogen-Like Hormonal Activity

Licorice flavonoids, particularly glabridin, have mild estrogen-like (phytoestrogenic) activity in laboratory and animal studies. This raises a theoretical concern for people with hormone-sensitive conditions, and licorice more broadly has been linked to effects on reproductive hormones. Whether the flavonoid doses delivered by chewed DGL produce clinically relevant hormonal effects in humans is not established, and evidence specific to DGL is sparse.

Magnitude: Not quantified in available studies.

Low 🟥

Mild Gastrointestinal Upset

A minority of users report mild nausea, loose stools, or a lingering sweet taste, generally transient and not clearly exceeding placebo rates in trials. These effects are minor and typically resolve with continued use or a lower dose. Chewable tablets are sometimes disliked for taste or texture rather than for true side effects.

Magnitude: In controlled trials DGL was generally well tolerated, with mild gastrointestinal complaints uncommon and not consistently above placebo.

Additive Potassium Loss with Certain Medications

If a product retains glycyrrhizin, its potassium-lowering effect can add to that of potassium-wasting drugs (such as some diuretics) or amplify the danger of drugs sensitive to low potassium (such as digoxin). This risk is again driven by residual glycyrrhizin rather than the flavonoids, and is negligible with genuinely deglycyrrhizinated product.

Magnitude: Not quantified in available studies.

Speculative 🟨

Pregnancy and Preterm-Birth Concerns

Heavy maternal intake of glycyrrhizin-containing licorice has been associated in observational research with preterm birth and effects on offspring; whether well-deglycyrrhizinated DGL shares any of this risk is unknown. Given the uncertainty and the difficulty of guaranteeing glycyrrhizin content, this is treated as a caution based on whole-licorice data extrapolated to DGL.

Unknown Very-Long-Term Safety of Concentrated Flavonoid Extracts

Standardized, concentrated flavonoid extracts deliver higher and more consistent doses of compounds such as glabridin than traditional licorice, and the consequences of continuous multi-year use have not been formally studied. Any concern here is theoretical and based on the general principle that concentrated botanical actives warrant long-term monitoring.

Risk-Modifying Factors

  • Genetic and metabolic susceptibility: individual differences in how gut bacteria and the SULT2A1 enzyme process glycyrrhizin metabolites strongly influence who develops pseudohyperaldosteronism; some people react to small residual amounts while others tolerate more.

  • Baseline blood pressure and potassium: people who already have elevated blood pressure or low-normal potassium are more likely to be tipped into clinically significant hypertension or hypokalemia by any residual glycyrrhizin.

  • Pre-existing conditions: heart failure, kidney disease, uncontrolled hypertension, and liver disease all raise vulnerability to fluid retention and electrolyte disturbance from residual glycyrrhizin.

  • Sex-based differences: hormone-sensitive conditions (more common in women) heighten the theoretical relevance of the flavonoids’ estrogen-like activity; classic licorice toxicity itself does not show a strong, consistent sex difference.

  • Age-related considerations: older adults have reduced 11β-HSD2 activity and kidney clearance, making them more prone to glycyrrhizin-induced blood-pressure and potassium effects even at lower intakes.

  • Product quality: the single largest modifier is whether the product is genuinely and fully deglycyrrhizinated and third-party tested, since independent testing has repeatedly found excess glycyrrhizin in “DGL” products.

Key Interactions & Contraindications

  • Antihypertensive drugs (for example, ACE inhibitors [angiotensin-converting-enzyme inhibitors, a class of blood-pressure drugs], angiotensin-receptor blockers, calcium-channel blockers): caution — residual glycyrrhizin can raise blood pressure and blunt these drugs’ effect; monitor blood pressure.

  • Diuretics, especially thiazides and loop diuretics (hydrochlorothiazide, furosemide): caution — additive potassium loss can cause significant hypokalemia; monitor serum potassium.

  • Digoxin: serious caution — low potassium from residual glycyrrhizin increases the risk of digoxin toxicity and dangerous heart rhythms; separate use and monitor potassium closely.

  • Corticosteroids (prednisone and similar): caution — glycyrrhizin can prolong and intensify steroid activity; relevant only if the product is incompletely deglycyrrhizinated.

  • Warfarin and other drugs with narrow safety margins: monitor — licorice constituents may alter drug metabolism through effects on liver enzymes; watch for changes in drug effect.

  • Over-the-counter agents: stimulant laxatives and non-prescription diuretics can add to potassium loss from any residual glycyrrhizin; NSAIDs are not adversely affected by DGL and may be a rational co-target for its protective effect.

  • Supplements with additive effects: other licorice-, glycyrrhizin-, or glycyrrhetinic-acid-containing products (including some “adrenal support” blends and licorice teas) stack glycyrrhizin exposure and raise pseudohyperaldosteronism risk; potassium-depleting herbs likewise add to the electrolyte burden. Acid-suppressing supplements or drugs (H2 blockers [histamine H2-receptor antagonists, which reduce stomach acid], PPIs [proton pump inhibitors, strong acid-blocking drugs]) can be combined with DGL, which targets a different, protective mechanism.

  • Populations who should avoid or use only under supervision: uncontrolled hypertension (blood pressure above roughly 140/90 mmHg), heart failure (New York Heart Association class III–IV), chronic kidney disease (eGFR — estimated glomerular filtration rate, a measure of kidney function — below 60), documented hypokalemia (potassium below 3.5 mmol/L), primary aldosteronism, pregnancy, and hormone-sensitive cancers. These cautions apply most strongly to products that cannot verify near-complete removal of glycyrrhizin.

Risk Mitigation Strategies

  • Choose fully deglycyrrhizinated, third-party-tested product: because independent testing found excess glycyrrhizin in about half of DGL products, selecting a brand that documents glycyrrhizin content below 3% and carries independent verification is the most important step to prevent pseudohyperaldosteronism.

  • Check blood pressure and potassium periodically: to catch residual-glycyrrhizin effects early, measure blood pressure at home (target under 120/80 mmHg) and check serum potassium (functional target 4.0–4.5 mmol/L) at baseline and after a few weeks of regular use, especially in older adults or those on blood-pressure or heart medications.

  • Avoid stacking licorice sources: to prevent cumulative glycyrrhizin exposure and the resulting high blood pressure and low potassium, do not combine DGL with licorice tea, licorice candy, or “adrenal” blends containing licorice.

  • Use the lowest effective dose for the shortest needed period: to limit both electrolyte risk and the unknowns of very-long-term concentrated-extract use, typical practice is short courses (for example, 2–4 weeks for symptom flares) rather than indefinite daily use unless symptoms recur.

  • Separate from potassium-sensitive drugs and monitor: for anyone on digoxin or diuretics, closer potassium monitoring (and clinician involvement) mitigates the risk that any residual glycyrrhizin triggers arrhythmia or toxicity.

Therapeutic Protocol

  • Standard chewable protocol: leading integrative practitioners describe chewing one to two DGL tablets (about 380–400 mg each) roughly 20 minutes before meals, up to three times daily, so the extract mixes with saliva and coats the upper digestive tract; this is the most commonly cited approach for reflux and indigestion.

  • Classic ulcer-healing protocol: the historical peptic-ulcer regimen used higher doses — on the order of 760 mg of DGL taken three times daily before meals for several weeks — reflecting the doses used in the original controlled trials.

  • Standardized-extract protocol: for standardized flavonoid extracts (for example, GutGard), the studied doses are much lower — about 75 mg twice daily for indigestion and around 150 mg daily for H. pylori suppression — because the active flavonoids are concentrated; this is the approach popularized by manufacturers of standardized extracts and used in the modern trials.

  • Best time of day: dosing is tied to meals rather than clock time; taking DGL about 20 minutes before eating, and additionally at bedtime for nighttime reflux, aligns coverage with symptom triggers.

  • Half-life and duration of effect: DGL’s action is largely local and short-lived, and its flavonoids have low absorption and relatively short measured half-lives, which is why practitioners favor divided dosing before each meal rather than a single daily dose.

  • Single versus split dosing: split dosing before each meal is standard, because the protective mucosal effect is transient and needs to be renewed around eating.

  • Genetic considerations: individual variation in gut-bacterial and SULT2A1 metabolism of any residual glycyrrhizin affects tolerance more than it affects the flavonoids’ benefit, so genotype mainly informs caution around product quality rather than dose of the active fraction.

  • Sex-based considerations: no sex-specific dosing is established; the mild estrogen-like activity of the flavonoids is a caution for hormone-sensitive conditions rather than a dosing adjustment.

  • Age-related considerations: older adults are typically started at the lower end of the dose range and with fully deglycyrrhizinated, tested product, given their heightened sensitivity to any residual glycyrrhizin.

  • Baseline biomarkers: checking baseline blood pressure and potassium before regular use helps individualize whether and how much DGL is appropriate, particularly for those on interacting medications.

  • Pre-existing conditions: people with hypertension, heart failure, kidney disease, or on digoxin or diuretics are guided toward the most rigorously deglycyrrhizinated products and closer monitoring, or toward avoiding DGL altogether.

Discontinuation & Cycling

  • Short-term versus lifelong use: DGL is generally used as a short-term or as-needed therapy for symptom flares and mucosal healing rather than as an indefinite lifelong supplement; courses of a few weeks are typical.

  • Withdrawal effects: no true withdrawal syndrome is described for DGL itself; symptoms such as heartburn may simply return if the underlying cause persists after stopping.

  • Tapering: no taper is required for DGL; if a product contained residual glycyrrhizin and caused elevated blood pressure or low potassium, those effects reverse after discontinuation and warrant monitoring rather than tapering.

  • Cycling: cycling is commonly suggested — using DGL during symptomatic periods and pausing when well — both to limit any residual-glycyrrhizin exposure and because there is no established benefit to continuous long-term dosing.

  • Reassessment: practitioners typically reassess after 2–4 weeks; persistent or alarm symptoms (bleeding, weight loss, difficulty swallowing) prompt medical evaluation rather than continued self-treatment.

Sourcing and Quality

  • Verify true deglycyrrhizination: the defining quality issue is whether glycyrrhizin has actually been reduced to below about 3%; reputable products state this and, ideally, provide test data, since independent testing found many “DGL” products retained excess glycyrrhizin.

  • Prefer third-party testing: look for independent verification (for example, ConsumerLab approval or equivalent certification) confirming both low glycyrrhizic acid and accurate flavonoid content.

  • Choose an appropriate form: chewable tablets or powders are preferred for upper-gut and reflux use because saliva mixing and mucosal contact are part of the mechanism; standardized flavonoid extracts (such as GutGard) offer more consistent dosing where a defined active content is desired.

  • Reputable brands and preparations: products from established supplement manufacturers with published testing, and standardized extracts with characterized flavonoid content, are generally more reliable than unspecified licorice-root products; avoid ordinary licorice supplements or candy as substitutes, since they retain glycyrrhizin.

  • Check labels for stacking risk: confirm the product is not combined with additional licorice or glycyrrhizin-containing ingredients in “digestive” or “adrenal” blends, which reintroduces the very risk deglycyrrhizination removes.

Practical Considerations

  • Time to effect: symptom relief for indigestion and reflux is often reported within about one to two weeks; canker-sore healing occurs over roughly 4–8 days, while ulcer healing protocols run several weeks.

  • Common pitfalls: the most frequent mistakes are swallowing capsules whole when a chewable is needed for upper-gut contact, using ordinary licorice (with glycyrrhizin) instead of true DGL, stacking multiple licorice sources, and expecting DGL to relieve reflux caused by non-mucosal mechanisms.

  • Regulatory status: DGL is sold as a non-prescription dietary supplement in most markets and is not approved as a drug for any condition; supplement regulation does not guarantee that label glycyrrhizin claims are accurate, which is why independent testing matters.

  • Cost and accessibility: DGL is inexpensive and widely available over the counter; cost and access are not meaningful barriers, so quality verification is the more relevant practical concern.

  • Interpretation of “natural”: being plant-derived does not make DGL free of risk; its safety depends almost entirely on the completeness of glycyrrhizin removal.

Interaction with Foundational Habits

  • Sleep: indirect and generally favorable — by easing nighttime reflux and upper-gut discomfort when taken before bed, DGL may improve sleep quality; a poorly deglycyrrhizinated product could theoretically disturb sleep through raised blood pressure, but this is uncommon.

  • Nutrition: direct and central — DGL is meant to be taken about 20 minutes before meals so it coats the gut ahead of food; it pairs logically with avoidance of personal reflux triggers (for some, large late meals, alcohol, or highly acidic foods), and unlike acid-suppressing drugs it does not impair the stomach acid needed for absorbing nutrients such as vitamin B12, iron, and magnesium.

  • Exercise: largely none/indirect — DGL does not blunt or enhance training adaptations; its only exercise-relevant caveat is that residual glycyrrhizin plus heavy sweating and potassium loss could compound electrolyte disturbance, an argument for verified product in very active users.

  • Stress management: indirect — because stress worsens functional dyspepsia and reflux, stress-reduction practices complement DGL by addressing an upstream driver of the symptoms DGL soothes; note that DGL, unlike whole licorice, does not raise cortisol, so it is not a stimulating “adrenal” agent.

Monitoring Protocol & Defining Success

Baseline assessment before regular use focuses on the systems affected by any residual glycyrrhizin — blood pressure and electrolytes — plus documentation of the symptoms being targeted. This is most important for older adults and anyone taking blood-pressure, heart, or diuretic medications.

Ongoing monitoring is light for a well-deglycyrrhizinated product used short-term: recheck blood pressure and potassium after about 2–4 weeks of regular use, then only if symptoms, medications, or products change. Those on interacting drugs or using higher doses warrant checks every few weeks during active use.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <120/80 mmHg Detect glycyrrhizin-related rise in pressure Home measurement seated after 5 min rest; conventional threshold for concern is 130/80–140/90 mmHg
Serum potassium 4.0–4.5 mmol/L Detect glycyrrhizin-related potassium loss Conventional reference 3.5–5.0 mmol/L; no fasting needed; check sooner if on diuretics or digoxin
Plasma renin activity and aldosterone Within lab reference (both low in pseudoaldosteronism) Confirm pseudohyperaldosteronism if blood pressure rises or potassium falls Morning sample; only needed if screening values are abnormal
H. pylori stool antigen or urea breath test Negative Confirm eradication when DGL is used for H. pylori Stop acid-suppressing drugs ~2 weeks before testing; breath test requires fasting

Qualitative markers of success are often more informative day to day than labs:

  • Frequency and intensity of heartburn or regurgitation
  • Post-meal fullness, bloating, and upper-abdominal pain
  • Canker-sore frequency, size, and healing time
  • Overall digestive comfort and, indirectly, sleep quality when nighttime reflux improves

Emerging Research

Research is framed for readers weighing DGL as a gut-protective and longevity-relevant option; the most active questions concern standardized extracts, H. pylori adjunct use, and long-term safety.

  • Ongoing H. pylori adjunct trial: a not-yet-recruiting randomized study, NCT06881524 (planned 374 participants), tests low-dose amoxicillin combined with licorice and lotus-root powder against high-dose amoxicillin for H. pylori, with eradication rate as the primary endpoint — directly relevant to DGL’s adjunct role.

  • Completed oral-health trials: a randomized trial of licorice extract for cavity prevention, NCT03684993 (63 participants), and a trial of licorice mucoadhesive films versus a topical steroid for mouth sores, NCT02075749 (60 participants), extend the mucosal-healing evidence into the mouth.

  • Standardization and dosing: future work reproducing the standardized-extract dyspepsia findings (Raveendra et al., 2012) in larger, longer trials could move functional-indigestion relief from medium toward high-confidence evidence, or fail to replicate it.

  • Head-to-head against acid suppression: modern trials comparing DGL with PPIs for reflux and ulcer healing are lacking; such studies could either strengthen or weaken the case for DGL as a substitute rather than a complement.

  • Adjunct-eradication meta-analysis: the polyphenol meta-analysis (Wang et al., 2023) suggests a modest add-on benefit for H. pylori that larger licorice-specific trials could confirm or overturn.

  • Long-term and hormonal safety: the phytoestrogenic activity of glabridin and the unknown consequences of years of concentrated-extract use are open questions; safety-focused reviews of licorice toxicity (Ceccuzzi et al., 2023) frame why product-quality monitoring will remain central.

Conclusion

DGL is a processed form of licorice root with most of the blood-pressure-raising compound removed, leaving plant flavonoids that coat and protect the lining of the mouth, stomach, and gut. The strongest evidence supports its soothing, healing role for recurrent mouth ulcers, with encouraging but more limited support for indigestion and for healing stomach and upper-intestinal ulcers. Its possible roles in easing acid reflux, curbing a common stomach bacterium, and shielding the gut from painkiller damage are plausible but rest on smaller or older studies. A recurring theme is that DGL works by strengthening the gut’s own defenses rather than by shutting off stomach acid, which is part of its appeal for people who want to avoid long-term acid-blocking drugs.

The evidence base is uneven: a few good modern studies sit alongside small, dated trials, and much of the mechanistic promise is not yet confirmed in people. The most important safety point is not the flavonoids but product quality — independent testing has found many “DGL” products still contain enough of the removed compound to raise blood pressure and lower potassium. Overall, DGL emerges as a low-cost, generally well-tolerated option whose real-world safety and value hinge on choosing a genuinely and fully processed, independently verified product.

Top - Benefits - Risks - Protocol